Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer

被引:0
作者
Kohei Shitara
Keitaro Matsuo
Ayako Mizota
Chihiro Kondo
Motoo Nomura
Daisuke Takahari
Tomoya Yokota
Takashi Ura
Seiji Ito
Akira Sawaki
Masahiro Tajika
Hiroki Kawai
Kei Muro
机构
[1] Aichi Cancer Center Hospital,Department of Clinical Oncology
[2] Aichi Cancer Center Research Institute,Division of Epidemiology and Prevention
[3] Aichi Cancer Center Hospital,Department of Surgery
[4] Aichi Cancer Center Hospital,Department of Gastroenterology
来源
Gastric Cancer | 2011年 / 14卷
关键词
Gastric cancer; Chemotherapy; Fluorouracil; Platinum agent; Paclitaxel; Irinotecan;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:155 / 160
页数:5
相关论文
共 97 条
[1]  
Van Cutsem E(2006)Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991-4997
[2]  
Moiseyenko VM(2008)Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36-46
[3]  
Tjulandin S(2008)S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215-221
[4]  
Majlis A(2009)Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Ann Oncol 20 666-673
[5]  
Constenla M(2010)Multicenter phase III comparison of cisplatin/s-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial J Clin Oncol 28 1547-1553
[6]  
Boni C(2010)Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407) J Clin Oncol 28 18s-1069
[7]  
Cunningham D(2010)Survival prolongation after treatment failure in patients with advanced gastric cancer (AGC): results from combined analysis of JCOG9205 and JCOG9912 J Clin Oncol 28 15s-1457
[8]  
Starling N(2009)Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 1063-59
[9]  
Rao S(2007)Irinotecan plus S-1 (IRIS) versus S-1 alone as first line treatment for advanced gastric cancer: preliminary results of a randomized phase III study (GC0301/TOP-002) J Clin Oncol 25 18 s-2909
[10]  
Iveson T(2008)Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Ann Oncol 19 1450-1214